Logo

GCTK

GlucoTrack, Inc.

GCTK

GlucoTrack, Inc. • NASDAQ
$6.80 ▲ 6.92% (+0.44)
Market Cap $3.86 M
52w High $468.00
52w Low $4.22
Dividend Yield 0%
P/E -0.01
Volume 27.19K
Outstanding Shares 567.46K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $4.3M ▼ $-4.171M ▲ 0% $4.64 ▲ $-4.162M ▲
Q2-2025 $0 $4.785M ▲ $-4.756M ▲ 0% $-9.62 ▼ $-4.745M ▲
Q1-2025 $0 $3.49M ▼ $-6.833M ▲ 0% $-0.67 ▲ $-6.825M ▲
Q4-2024 $0 $3.84M ▲ $-10.094M ▼ 0% $-21.75 ▼ $-10.08M ▼
Q3-2024 $0 $3.241M $-5.087M 0% $-18.18 $-3.229M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $7.869M ▼ $8.29M ▼ $5.539M ▲ $2.751M ▼
Q2-2025 $9.555M ▲ $10.21M ▲ $3.33M ▲ $6.88M ▼
Q1-2025 $9.1M ▲ $9.612M ▲ $2.354M ▼ $7.258M ▲
Q4-2024 $5.617M ▲ $5.932M ▲ $18.932M ▲ $-13M ▼
Q3-2024 $346K $826K $4.848M $-4.022M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-4.756M ▲ $-3.744M ▼ $0 ▲ $4.16M ▼ $445K ▼ $-3.744M ▼
Q1-2025 $-6.833M ▲ $-2.939M ▲ $-9K ▼ $6.395M ▼ $3.483M ▼ $-2.948M ▲
Q4-2024 $-10.094M ▼ $-3.499M ▲ $0 ▲ $8.783M ▲ $5.271M ▲ $-3.499M ▲
Q3-2024 $-5.087M ▼ $-4.142M ▼ $-33K ▼ $4.38M ▲ $188K ▲ $-4.175M ▼
Q2-2024 $-4.489M $-1.907M $-12K $580K $-1.339M $-1.919M

Five-Year Company Overview

Income Statement

Income Statement GlucoTrack’s income statement reflects a very early‑stage medical device company. It has not generated product revenue over the past several years, so all activity is essentially research, development, and corporate overhead. Operating losses have been modest in absolute terms but consistent, which is typical for a pre‑commercial firm. The recent appearance of net income likely stems from accounting or financing one‑offs rather than any underlying business profitability. Reported earnings per share swing wildly because the share count has been repeatedly consolidated through reverse splits, so per‑share figures are not a reliable guide to economic performance. Overall, the income statement shows a company still firmly in the development phase with no commercial engine yet in place.

Balance Sheet

Balance Sheet The balance sheet has been very small, with limited assets and cash and no meaningful debt historically. Equity has recently turned negative, signaling that accumulated losses now exceed the book value of assets. That is not unusual for a small, clinical‑stage company, but it highlights financial fragility and dependence on fresh capital. The separate disclosure that the company holds a moderate cash cushion to fund its 2025 plan suggests it has raised more funds since the historical balance sheet snapshots. Even so, GlucoTrack’s financial strength rests almost entirely on its ability to keep accessing equity or strategic financing rather than on internally generated resources.

Cash Flow

Cash Flow Cash flow patterns are what you would expect from a pre‑revenue med‑tech firm: cash going out for operating expenses, virtually nothing coming in from customers, and minimal spending on physical assets. Operating and free cash flow have been negative but not large in absolute dollar terms so far. As the company moves into larger human trials, that cash burn is likely to rise. Since there is no product revenue to offset these costs, the sustainability of the cash flow profile depends on continued success in raising capital and tightly managing spending during the long clinical and regulatory path.

Competitive Edge

Competitive Edge GlucoTrack is aiming at a very large and already crowded diabetes monitoring market dominated by major players with well‑established devices, strong brands, and deep commercial resources. Its angle is a differentiated, fully implantable, long‑duration glucose monitor that could appeal to patients who dislike frequent sensor changes or visible wearables. The main direct implantable competitor today offers shorter‑term implants, so GlucoTrack’s proposed multi‑year implant life and absence of an external device are meaningful differentiators on paper. However, the company currently has no approved product, no established sales infrastructure, and must still prove safety, reliability, ease of use, and economic value to patients, physicians, and payers. Its competitive position is therefore idea‑rich but execution‑dependent, with significant advantages possible if the technology works as planned, and significant risk if larger incumbents innovate quickly or if adoption barriers are higher than expected.

Innovation and R&D

Innovation and R&D Innovation is the core of GlucoTrack’s story. The company is developing a long‑term implantable sensor placed in a central vein to measure glucose directly from blood rather than from the fluid under the skin. Early human data suggest accuracy and safety that could be competitive with today’s leading devices, while offering a “set‑it‑and‑forget‑it” experience with no on‑body hardware and smartphone connectivity. Research and development spending is focused on refining the sensor chemistry, ensuring long‑term stability, and running the clinical trials needed for regulatory approval. Upcoming milestones include regulatory submissions to allow larger U.S. studies and a multi‑center trial abroad to test long‑term performance. Manufacturing and data‑analytics partnerships are in place, which is encouraging, but the technology is still in the clinical validation stage, with all the usual scientific, regulatory, and timing uncertainties that implies.

Summary

GlucoTrack is a classic high‑uncertainty, development‑stage medical device company. Financially, it has no revenue, ongoing operating losses, negative free cash flow, and a fragile balance sheet that relies on periodic capital raises rather than on business profits. Strategically, it is pursuing a clearly differentiated and potentially disruptive product in a very large market, with early clinical signals that look encouraging and partnerships that help with manufacturing and analytics. At the same time, it faces powerful incumbents, demanding clinical and regulatory hurdles, and the constant need to secure funding through a lengthy development cycle. The company’s future will be shaped less by recent historical financials and more by its ability to deliver strong trial data, navigate the FDA process, build or partner for commercialization, and maintain adequate financing along the way.

NEWS

November 13, 2025 · 4:05 PM UTC

Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

Read more

November 3, 2025 · 4:05 PM UTC

Glucotrack, Inc. Encourages Shareholders to Vote

Read more

October 29, 2025 · 4:05 PM UTC

Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team

Read more

October 28, 2025 · 8:00 AM UTC

Glucotrack, Inc. Reminds Shareholders to Vote

Read more

September 11, 2025 · 8:00 AM UTC

Glucotrack to Participate in the Q3 Virtual Investor Summit

Read more